Equillium to acquire Metacrine in all-stock deal; adds $33M cash, MET642 candidate

Equillium, Inc.

All-stock merger adds ~$33M cash to Equillium's balance sheet, extending runway into 2024.
Transaction valued at 25% premium over Metacrine net cash (~$26M); EQ shares priced between $2.70 and $4.50.
Equillium assumes $15M Metacrine debt from K2 HealthVentures; retires its own $10M Oxford/SVB facility.
Acquisition includes MET642, a Phase 2-ready oral FXR agonist for ulcerative colitis; strategic partner sought.
Preston Klassen (Metacrine CEO) appointed to Equillium board; no Metacrine employees retained. Closing late 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.